61257-02-1

Basic information

• Product Name: mycaminosyltylonolide
• Synonyms: mycaminosyltylonolide;5-O-mycaminosyltylonolide
• CAS NO: 61257-02-1
• Molecular Formula: C₃₁H₅₁NO₁₀
• Molecular Weight: 597.741
• Mol File: 61257-02-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 799.9°C at 760 mmHg
• Flash Point: 437.6°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 1.36E-29mmHg at 25°C
• Refractive Index: 1.545
• CAS DataBase Reference: mycaminosyltylonolide(CAS DataBase Reference)
• NIST Chemistry Reference: mycaminosyltylonolide(61257-02-1)
• EPA Substance Registry System: mycaminosyltylonolide(61257-02-1)

Safety Data

• Hazardous Substances Data: 61257-02-1(Hazardous Substances Data)

Usage

Description

Mycaminosyltylonolide is a macrolide antibiotic derived from tylonolide, with a beta-D-mycaminosyl residue attached at position 5. It is a naturally occurring compound with potential pharmaceutical applications due to its antibiotic properties.

Uses

Used in Pharmaceutical Industry:
Mycaminosyltylonolide is used as an antibiotic agent for its ability to inhibit the growth of certain bacteria. Its unique structure allows it to target specific bacterial cells, making it a valuable compound in the development of new antibiotics to combat drug-resistant infections.
Used in Research and Development:
Mycaminosyltylonolide serves as a key compound in the study of macrolide antibiotics and their mechanisms of action. Researchers can use this compound to better understand the interactions between antibiotics and bacterial cells, potentially leading to the discovery of new antibiotic classes or improved drug delivery methods.
Used in Drug Synthesis:
As a derivative of tylonolide, mycaminosyltylonolide can be utilized in the synthesis of novel macrolide antibiotics with enhanced properties, such as increased efficacy, reduced side effects, or improved drug resistance profiles. This application can contribute to the development of more effective treatments for bacterial infections.

InChI:InChI=1/C31H51NO10/c1-8-25-22(16-34)13-17(2)9-10-23(35)18(3)14-21(11-12-33)30(19(4)24(36)15-26(37)41-25)42-31-29(39)27(32(6)7)28(38)20(5)40-31/h9-10,12-13,18-22,24-25,27-31,34,36,38-39H,8,11,14-16H2,1-7H3/b10-9+,17-13+/t18-,19+,20-,21+,22-,24-,25-,27+,28-,29-,30-,31+/m1/s1

Upstream product

• 1401-69-0 tylosin 
• 1401-69-0 15-[[(6-deoxy-2,6-di-O-methyl-β-D-allopyranosyl)-oxy]methyl]-6-[[3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-α-L-ribo-hexapyranosyl)-3-(dimethylamino)-β-D-glucopyranosyl]oxy]-16-ethyl-4-hydroxy-5,9,13-trimethyl-2,10-oxo-oxocyclo-hexadeca-11,13-diene-7... 
• 11032-98-7 demycarosyltylosin 
• 90232-64-7 C₆₀H₁₀₃N₃O₂₀SSi 
• 90233-04-8 C₅₈H₁₀₁N₃O₁₉SSi 
• 90232-65-8 2',4''-di-O-acetyl-20-deoxo-20-<(4,4-dioxothiomorpholino)imino>tylosin 
• 90233-00-4 23-O-demycinosyl-20-deoxo-20-<(4,4-dioxothiomorpholino)imino>tylosin 

Downstream Products

• 1438281-75-4 23-(4-phenyl-1H-1,2,3-triazol-1-yl)-23-deoxy-5-O-mycaminosyltylonolide 
• 1235514-52-9 C₄₄H₆₇N₃O₁₃ 
• 84710-26-9 (7E,9E)-(2S,3aR,5R,6S,11R,12R,16R,17S,17aS)-12-Ethyl-6,16-dihydroxy-2-methoxy-5,9,17-trimethyl-11-trityloxymethyl-2,3,3a,4,5,6,11,12,15,16,17,17a-dodecahydro-1,13-dioxa-cyclopentacyclohexadecen-14-one 
• 81114-73-0 (7E,9E)-(2S,3aR,5R,6R,11R,12R,16R,17S,17aS)-12-Ethyl-6,16-dihydroxy-2-methoxy-5,9,17-trimethyl-11-trityloxymethyl-2,3,3a,4,5,6,11,12,15,16,17,17a-dodecahydro-1,13-dioxa-cyclopentacyclohexadecen-14-one 
• 61219-81-6 Tylonolide Hemiacetal 
• 83114-35-6 (3R,4S)-4-[(2S,3R,5S)-3-((4E,6E)-(2R,3S,8R,9R)-3,9-Dihydroxy-2,6-dimethyl-8-trityloxymethyl-undeca-4,6-dienyl)-5-methoxy-tetrahydro-furan-2-yl]-3-hydroxy-pentanoic acid methyl ester 
• 81114-52-5 20-O-Methyl-23-O-trityltylonolide Hemiacetal 
• 81132-63-0 20-O-Methyl-23-O-trityltylonolide Hemiacetal 
• 83061-10-3 (3R,4S)-4-[(2S,3R,5S)-3-((4E,6E)-(2R,3S,8R,9R)-3,9-Dihydroxy-2,6-dimethyl-8-trityloxymethyl-undeca-4,6-dienyl)-5-methoxy-tetrahydro-furan-2-yl]-3-hydroxy-pentanoic acid 
• 50507-46-5 deepoxycirramycin A1 
• 81661-90-7 5-O-mycaminosylprotylonolide 
• 61219-81-6 tylonolide 5,20-hemiacetal 
• 873782-92-4 phosphoric acid 12-(4-dimethylamino-3,5-dihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-11-[1,3]dioxolan-2-ylmethyl-2-ethyl-14-hydroxy-5,9,13-trimethyl-16-oxo-8-[3-(quinolin-6-yloxy)-propoxyimino]-oxacyclohexadeca-4,6-dien-3-ylmethyl ester diphenyl ester 

Relevant articles and documents

20. 23 - b piperidinyl - 5 - O - carbon mildew amine sugar base polyhydro - method for preparing lactone

The invention relates to a preparation method of macrolide, which is in particular to a preparation method of 20,23-dipiperidinyl-5-O-carbon mould amine glycosyl-tylosin lactone. The preparation method comprises the following steps: 1)dissolving 20,23-dipiperidinyl-5-O-carbon mould amine glycosyl-tylosin lactone in dichloromethane, adding a selective oxidant or a combination oxidizing agent system, generating an oxidation reaction, generating 20,23-dipiperidinyl-5-O-carbon mould amine glycosyl-tylosin lactone; 2)adding a solvent in 20,23-dipiperidinyl-5-O-carbon mould amine glycosyl-tylosin lactone, then adding piperidine and formic acid, generating a reductive amination to obtain 20,23-dipiperidinyl-5-O-carbon mould amine glycosyl-tylosin lactone. The preparation method has the advantages of short route and simple operation, and is suitable for industrial production.

TYLOSIN DERIVATIVES AND METHOD FOR PREPARATION THEREOF

The present invention relates to new macrolide derivatives, in particular new tylosin derivatives of the formula (Ila), a pharmaceutical or veterinary composition comprising the derivatives; a method for preparation thereof; a method for treating and/or preventing bacterial infections in an animal, wherein the method comprises administering the derivatives or the composition; and a use of the derivatives for the manufacture of medicaments for treating and/or preventing bacterial infections in an animal.

Peptide derivatives of tylosin-related macrolides

Approaches to the synthesis of model compounds based on the tylosin-related macrolides desmycosin and O-mycaminosyltylonolide were developed to study the conformation and topography of the nascent peptide chain in the ribosome tunnel using specially designed peptide derivatives of macrolide antibiotics. A method for selective bromoacetylation of desmycosin at the hydroxyl group of mycinose was developed, which involves preliminary acetylation of mycaminose. The reaction of the 4″-bromoacetyl derivative of the antibiotic with cesium salts of the dipeptide Boc-Ala-Ala-OH and the hexapeptide MeOTr-Gly-Pro-Gly-Pro- Gly-Pro-OH led to the corresponding peptide derivatives of desmycosin. The protected peptides Boc-Ala-Ala-OH, Boc-Ala-Ala-Phe-OH, and Boc-Gly-Pro-Gly-Pro- Gly-Pro-OH were condensed with the C23-hydroxyl group of O- mycaminosyltylonolide.